Establishing trial-level surrogacy of an intermediate endpoint for predicting survival benefit in future trials is extremely challenging because of the extrapolations required, but there are other useful drug development and patient management applications of intermediate endpoints.
from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2EoExcU
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου